The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
The avacta board had agreed to pay a man £300k a year.
A man of monumental power and experience in licensing deals all over planet Earth and people think it’s a goner 🤪🤪🤪🤪
This will climb like a monkey in a forest fire when the deal lands …make no mistake!!
Note: no monkeys were hurt in this experiment
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce the appointment of Dr Simon Bennett as Chief Business Officer of the Therapeutics Division.
Simon has over 26 years' commercial experience in the biopharma industry. He has worked with companies from large and mid-sized pharma such as Bristol-Myers-Squibb and Menarini Group to early stage biotechs, supporting business development and licensing activities in addition to being involved in all aspects of business and corporate development. Simon has been involved in over 80 commercial deals across Europe, North America, Australasia, Japan, Russia/CIS and South America.
Only 4 from England
https://www.fda.gov/media/110742/download
Https://www.fda.gov/about-fda/2023-oce-annual-report/ongoing-clinical-oncology-projects
Booking out orders mate
You only see about 30% of it
Without Bloomberg it’s pointless
Do not read to much into these
People on twitter going on about big chunks etc or mr £10k is back ffs
It’s all nonsense and plenty of Joe publics will buy or sell £50k now and again